Abstract: The present invention provides a double-stranded RNA which inhibits replication of influenza B viruses by RNA interference, in which the double-stranded RNA comprises an RNA having 19 to 25 nucleotides homologous with a part of an mRNA transcribed from a genomic RNA of the influenza B viruses and an antisense RNA thereof.

Abstract: The present invention provides a double-stranded RNA which inhibits replication of influenza B viruses by RNA interference, in which the double-stranded RNA comprises an RNA having 19 to 25 nucleotides homologous with a part of an mRNA transcribed from a genomic RNA of the influenza B viruses and an antisense RNA thereof.

Abstract: The present invention provides a double-stranded RNA which inhibits replication of influenza B viruses by RNA interference, in which the double-stranded RNA comprises an RNA having 19 to 25 nucleotides homologous with a part of an mRNA transcribed from a genomic RNA of the influenza B viruses and an antisense RNA thereof.

Abstract: There is provided a transfection device having a mixture (1) immobilized on a solid-phase support (3), the mixture including: a gene sample; a gene delivery material; and at least one compound selected from the group consisting of sericin, a hydrolysate thereof and a chemically modified product of sericin or a hydrolysate thereof.

Abstract: A cubic liquid crystal composition comprising at least one amphiphilic compound having the following general formula (1) and having an IV/OV value of 0.65 to 0.95, and water or an aqueous medium: wherein R represents a hydrophilic group; X and Y each independently represent a hydrogen atom or together form an oxygen atom; n is an integer of 0 to 4; and m is an integer of 0 to 3.

Abstract: The present invention provides a double-stranded RNA which inhibits replication of influenza B viruses by RNA interference, in which the double-stranded RNA comprises an RNA having 19 to 25 nucleotides homologous with a part of an mRNA transcribed from a genomic RNA of the influenza B viruses and an antisense RNA thereof.

Abstract: The present invention provides a method for deriving an upstream or downstream component of a component necessary for phenotypic alteration of a living organism, the method comprising the steps of: specifying a pathway of interest related to the phenotypic alteration and a reference pathway different from the pathway of interest, and specifying a stimulant of interest and a reference stimulant which respectively stimulate the pathway of interest and the reference pathway; giving the stimulant of interest to the living organism to identify a collection of components of interest necessary for the phenotypic alteration; giving the reference stimulant to the living organism to identify a collection of reference components necessary for the phenotypic alteration; calculating an intersection between the collections of the components of interest and the reference components; and calculating a differential collection by subtracting the intersection from the collection of components of interest.

Abstract: The present invention provides a method for deriving an upstream or downstream component of a component necessary for phenotypic alteration of a living organism, the method comprising the steps of: specifying a pathway of interest related to the phenotypic alteration and a reference pathway different from the pathway of interest, and specifying a stimulant of interest and a reference stimulant which respectively stimulate the pathway of interest and the reference pathway; giving the stimulant of interest to the living organism to identify a collection of components of interest necessary for the phenotypic alteration; giving the reference stimulant to the living organism to identify a collection of reference components necessary for the phenotypic alteration; calculating an intersection between the collections of the components of interest and the reference components; and calculating a differential collection by subtracting the intersection from the collection of components of interest.

Abstract: A cubic liquid crystal composition comprising at least one amphiphilic compound having the following general formula (1) and having an IV/OV value of 0.65 to 0.95, and water or an aqueous medium: wherein R represents a hydrophilic group; X and Y each independently represent a hydrogen atom or together form an oxygen atom; n is an integer of 0 to 4; and m is an integer of 0 to 3.

Abstract: The invention provides a method of preparing a biological components-containing solution suitable for clinical proteome analysis by mass spectrometry, electrophoresis, liquid chromatography or the like and an apparatus for the method.

Abstract: The present invention is directed to a process for preparing the following compound ##STR1## which is prepared starting from ##STR2## which is reacted succesively with 4-iodobenzyl or 4-bromobenzyl bromide, hydrazine and 1,4-dimethyl-1,3-cyclohexadiene, reduced and reacted with phenyltetrazole or suitably protected phenyltetrazole followed by removal

Abstract: The present invention provides a novel imidazole derivative having the chemical formula ##STR1## These compounds are useful for preventing or treating hypertension or congestive heart failure and have high activity, rapid action upon intravenous injection, good oral absorbtion, low toxicity, and long-lasting action. Also provided are pharmaceutical compositions which contain these compounds.

Abstract: Novel terpene amino alcohols having an antiallergic activity or an activity of improving cerebral function are provided. Also provided are medicinal uses of the alcohols.

Abstract: Novel terpene amino alcohols having an antiallergic activity or an activity of improving cerebral function are provided. Also provided are medicinal uses of the alcohols.

Abstract: Novel terpene amino alcohols having an antiallergic activity or an activity of improving cerebral function are provided. Also provided are medicinal uses of the alcohols.

Abstract: Novel terpene amino alcohols having an antiallergic activity or an activity of improving cerebral function are provided. Also provided are medicinal uses of the alcohols.

Abstract: A present invention provides a process for preparing a mixture of cyclic terpenoids of general formula (I), ##STR1## wherein R is a hydrogen atom or a lower alkyl group, and general formula (II), ##STR2## wherein R is defined as above, containing (I) predominant over (II) by the reaction of an acid with a cyclic terpenoid of general formula (II), or a mixture of cyclic terpenoids of general formulas (I) and (II), containing (II) predominant over (I).

Abstract: A process for preparing an allylic sulfone of the following general formula (I), ##STR1## wherein, R is a hydrogen atom or a lower alkyl group, and containing both cis and trans isomers, by a reaction of a compound selected from the group consisting of geranyl chloride, neryl chloride, and linalyl chloride with a phenyl sulfinate of the following general formula (III), ##STR2## wherein, R is a hydrogen atom, or a lower alkyl group, and M is a sodium atom or potassium atom, in the presence of (i) tetralkylammonium iodide in an anhydrous condition or (ii) a zinc halide and an iodide.

Abstract: Chlorinated olefins of general formula (I), ##STR1## wherein R is an alkyl, aralkyl, or alkenyl group substituted or not substituted by a lower acyloxy, lower alkyloxy, alkenyloxy or benzyloxy group, are prepared by the reaction of hypochlorous acid, generated by the reaction of sodium hypochlorite with a strong mineral acid, and olefins of general formula (II), ##STR2## wherein R is the same as defined above, in a two-phase system of water phase and organic solvent phase, not being miscible with water.

Abstract: A process for preparing .alpha.,.beta.-unsaturated aldehydes of the general formula (I) ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 are independently a hydrogen atom, or an alkyl or alkenyl group with or without being substituted with a lower acyloxy group. The aldehyde of the general formula (I) is prepared by reaction between an allylic chloride of the following general formula (IIa) ##STR2## in which R.sup.1, R.sup.2 and R.sup.3 have, respectively, the same meanings as defined above, and an amine oxide selected from the group consisting of tri(lower alkyl)amine N-oxides of the formula,R.sub.3.sup.4 N.sup.+ O.sup.-,in which R.sup.4 represents a lower alkyl group having from 2 to 4 carbon atoms, and N-lower alkylmorpholine N-oxides of the following formula ##STR3## in which R.sup.5 represents a lower alkyl group having from 1 to 4 carbon atoms. Alternatively, the aldehyde of the formula (I) is obtained by reaction between an allylic chloride of the following general formula (IIb) ##STR4## in which R.sup.